<DOC>
	<DOCNO>NCT02514746</DOCNO>
	<brief_summary>This study aim understand persistence Japanese encephalitis ( JE ) antibody response previously vaccinate child . The propose study phase 4 open-label trial enrol 818 Bangladeshi child previously participate lot lot consistency study ( JEV05 ) JE live attenuate SA 14-14-2 vaccine ( CD-JEV ) .</brief_summary>
	<brief_title>Long-term Immunogenicity After Receipt JE Vaccine Antibody Response Safety Booster Dose</brief_title>
	<detailed_description>Study participant previously immunize CD-JEV ( Clinical Trials identifier : NCT01567865 , JEV05 ) serum collect three four year initial vaccination ass long-term immunogenicity . Four year receive initial dose CD-JEV , eligible participant vaccinate second subcutaneous dose CD-JEV ass antibody response . Participants monitor safety 28 day follow receipt booster dose .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Participant JEV05 study receive one dose CDJEV . Resides Matlab Mirpur study area . At least one parent guardian willing provide write informed consent . Received second dose Japanese encephalitis vaccine within past three year . Received immunoglobulin and/or blood product within 90 day prior enrollment . Been diagnose primary acquire immunodeficiency , include HIV infection within past three year .</criteria>
	<gender>All</gender>
	<minimum_age>43 Months</minimum_age>
	<maximum_age>51 Months</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Japanese Encephalitis Vaccines</keyword>
	<keyword>Flavivirus Infections</keyword>
</DOC>